{'fraction_non_alphanumeric': 0.032692307692307694, 'fraction_numerical': 0.0, 'mean_word_length': 6.236111111111111, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Diphenylcyclopropenone for the treatment of cutaneous in‐transit melanoma metastases – results of a prospective, non‐randomized, single‐centre study

Current treatments for in‐transit melanoma (ITM) metastases are frequently invasive and do not improve overall survival. Recently, there has been increasing investigation into the use of topical agents. Diphenylcyclopropenone or diphencyprone (DPCP) is a novel, topical therapy that has been reported to have immune‐sensitizing properties useful in the treatment of ITM.